tag:blogger.com,1999:blog-7857054149675424609.post6110196510486737743..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: ASCO for RNAi Therapeutics in Line with Expectations, but Curious Nevertheless (Part I- ALN-VSP02)Dirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger4125tag:blogger.com,1999:blog-7857054149675424609.post-33923593647302273732012-06-08T18:00:05.619+00:002012-06-08T18:00:05.619+00:00Slides 19 and 20 of last year's ASCO presentat...Slides 19 and 20 of last year's ASCO presentation: http://www.alnylam.com/capella/wp-content/uploads/2011/06/ALN-VSP-PhI-ClinicalStudyResults-ASCO2011.pdfDirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-63877579775264962312012-06-08T14:18:12.433+00:002012-06-08T14:18:12.433+00:00Great. Can you kindly locate the reference? Greatl...Great. Can you kindly locate the reference? Greatly appreciated.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-92232754666451073322012-06-08T01:17:58.441+00:002012-06-08T01:17:58.441+00:00Correct me if I'm wrong: Alnylam was able to s...Correct me if I'm wrong: Alnylam was able to see 5' RACE product for one of the targets (VEGF) from the phase I VSP02 trial in 3 of 15 needle biopsy samples.Unknownhttps://www.blogger.com/profile/05205285919732112713noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-85850545703516874922012-06-07T15:58:04.281+00:002012-06-07T15:58:04.281+00:00Dirk,
As you indicated in your previous blog on th...Dirk,<br />As you indicated in your previous blog on the possibility of innate immune response as a potential mechanism for ALN-RSV. Do you know if Alnylam ever demonstrated the mode of action such as siRNA mediated cleavage in patient samples of either one of those two clinical trials? or what kind of dose were actually delivered to tumor?Anonymousnoreply@blogger.com